Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax Treated CLL in Routine Clinical Practice

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-19-0361
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Unfavourable Risk Factor Control After Coronary Events in Routine Clinical Practice

BMC Cardiovascular Disorders
Cardiovascular MedicineCardiology
2017English

How to Approach CLL in Clinical Practice

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Venetoclax–Obinutuzumab Elicits High Response Rates in CLL

Cancer Discovery
Oncology
2019English

Disclosing Clinical Adverse Events to Patients: Can Practice Inform Policy?

Health Expectations
EnvironmentalPublic HealthOccupational Health
2009English

Venetoclax‐induced Tumour Lysis Syndrome in Acute Myeloid Leukaemia

British Journal of Haematology
Hematology
2019English

Pcn84 - Total Cost of Care and Budget Impact for Patients With CLL Treated With Venetoclax

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Improved Clinical Outcomes and Physical Activity in Patients With Rheumatoid Arthritis Treated With Originator Adalimumab in Routine Clinical Practice

International Journal of Clinical Rheumatology
Rheumatology
2018English

Determinants of Virological Outcome and Adverse Events in African Children Treated With Paediatric Nevirapine Fixed-Dose-Combination Tablets

AIDS
Infectious DiseasesAllergyImmunology
2017English

Illuminating Aberrant mRNA Events in CLL

Cancer Discovery
Oncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy